The Targeted Radiopharmaceuticals (TRP) Summit: an industry-led platform that discusses challenges and opportunities faced by developers of theranostic radio ligand therapies. Topics such as the identification and validation of new targets and ways to improve the current clinical design methodologies will be discussed by speakers and panels.
For the 2021 edition of this conference, it is possible to attend either in-person in Berlin or remotely via a dedicated digital networking platform with all the access to the conference content.
Jan van Bodegom
Chief Executive Officer Coretag
Jan van Bodegom has vast experience in the medical field, from working as a surgeon to healthcare management and the development of medical devices. In 2000, he graduated from Erasmus University Medical School in Rotterdam as a surgeon and went on to work in Bernhoven Hospital in Uden, the Netherlands, for 10 years. He founded the Alexander Monro Hospital, the first breast cancer hospital in Europe and he co-founded the first focus clinic for prostate cancer: Reinier Haga Prostate Cancer Center, Delft.
He is the CEO of Coretag, a company specialized in developing radio ligands, which detect and target necrotic cells in the body.
“Accelerated availability of targeted alpha therapy for patients can make a real difference”
When: Tuesday 7 until Thursday 9, December 2021
Where: Berlin and online
If you wish to learn more about the speakers, the programme or registration, please check the TRP Summit website.
If you want to get in touch about the TRP Summit or want to learn more about FIELD-LAB and Advancing Nuclear Medicine, please leave your contact information in this form. We will reach out to you as soon as possible.